other material
confidence high
sentiment positive
materiality 0.85
Aclaris ATI-052 Phase 1b hits: 45% placebo-adjusted EASI in AD, 59% FeNO cut in asthma
Aclaris Therapeutics, Inc.
- AD: ATI-052 480 mg weekly cut EASI 58% vs 13% placebo at day 57, a 45% placebo-adjusted mean improvement; EASI-50 was 78% placebo-adjusted.
- Itch: PP-NRS improved 43% placebo-adjusted at day 57 (38% active vs 5% worsening placebo); 33% achieved placebo-adjusted PP-NRS4 response.
- Asthma: single 480 mg dose cut FeNO 59% (45 ppb) at day 15 vs 15% placebo; 58% reached FeNO ≤25 ppb; FEV1 improved 200 mL placebo-adjusted.
- Safety: no Grade 3/4 TEAEs, no discontinuations, no conjunctivitis; injection-site reactions transient and mostly Grade 1.
- Aclaris will prioritize ATI-052 in eosinophilic esophagitis, planning a Phase 2b trial in early 2027; preliminary cash was $204.6M at Sept 30, 2026.